Dr. Grignani Discusses the Safety Profile of Trabectedin in Sarcoma

Giovanni Grignani, MD
Published: Thursday, Mar 09, 2017



Giovanni Grignani, MD, medical oncologist, Candiolo Cancer Institute IRCCS, discusses the safety profile of trabectedin (Yondelis) in the treatment of sarcoma.

The aging population of patients with sarcoma have several comorbidities, which can disrupt the course of treatment. But, in a recent phase II study, trabectedin showed a favorable safety profile with no toxicity related deaths in this population.

This regimen requires very careful premedication with steroids and close follow up, though, says Grignani—as there are patients who might develop unusual toxicities.
 


Giovanni Grignani, MD, medical oncologist, Candiolo Cancer Institute IRCCS, discusses the safety profile of trabectedin (Yondelis) in the treatment of sarcoma.

The aging population of patients with sarcoma have several comorbidities, which can disrupt the course of treatment. But, in a recent phase II study, trabectedin showed a favorable safety profile with no toxicity related deaths in this population.

This regimen requires very careful premedication with steroids and close follow up, though, says Grignani—as there are patients who might develop unusual toxicities.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize OutcomesOct 31, 20182.0
Publication Bottom Border
Border Publication
x